Anti-Inflammatory Effects of Fucoxanthinol in LPS-Induced RAW264.7 Cells through the NAAA-PEA Pathway.
Amides
/ metabolism
Amidohydrolases
/ metabolism
Animals
Anti-Inflammatory Agents
/ pharmacology
Cytokines
/ drug effects
Enzyme Inhibitors
/ pharmacology
Ethanolamines
/ metabolism
Inflammation
/ enzymology
Lipopolysaccharides
/ pharmacology
Mice
Nitric Oxide
/ metabolism
Oxazoles
PPAR alpha
/ antagonists & inhibitors
Palmitic Acids
/ metabolism
RAW 264.7 Cells
Tyrosine
/ analogs & derivatives
beta Carotene
/ analogs & derivatives
NAAA
PEA
PPAR-α
fucoxanthinol
inflammation
Journal
Marine drugs
ISSN: 1660-3397
Titre abrégé: Mar Drugs
Pays: Switzerland
ID NLM: 101213729
Informations de publication
Date de publication:
21 Apr 2020
21 Apr 2020
Historique:
received:
22
03
2020
revised:
15
04
2020
accepted:
15
04
2020
entrez:
25
4
2020
pubmed:
25
4
2020
medline:
17
2
2021
Statut:
epublish
Résumé
Palmitoylethanolamide (PEA) is an endogenous lipid mediator with powerful anti-inflammatory and analgesic functions. PEA can be hydrolyzed by a lysosomal enzyme N-acylethanolamine acid amidase (NAAA), which is highly expressed in macrophages and other immune cells. The pharmacological inhibition of NAAA activity is a potential therapeutic strategy for inflammation-related diseases. Fucoxanthinol (FXOH) is a marine carotenoid from brown seaweeds with various beneficial effects. However, the anti-inflammatory effects and mechanism of action of FXOH in lipopolysaccharide (LPS)-stimulated macrophages remain unclear. This study aimed to explore the role of FXOH in the NAAA-PEA pathway and the anti-inflammatory effects based on this mechanism. In vitro results showed that FXOH can directly bind to the active site of NAAA protein and specifically inhibit the activity of NAAA enzyme. In an LPS-induced inflammatory model in macrophages, FXOH pretreatment significantly reversed the LPS-induced downregulation of PEA levels. FXOH also substantially attenuated the mRNA expression of inflammatory factors, including inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), and markedly reduced the production of TNF-α, IL-6, IL-1β, and nitric oxide (NO). Moreover, the inhibitory effect of FXOH on NO induction was significantly abolished by the peroxisome proliferator-activated receptor α (PPAR-α) inhibitor GW6471. All these findings demonstrated that FXOH can prevent LPS-induced inflammation in macrophages, and its mechanisms may be associated with the regulation of the NAAA-PEA-PPAR-α pathway.
Identifiants
pubmed: 32326173
pii: md18040222
doi: 10.3390/md18040222
pmc: PMC7230820
pii:
doi:
Substances chimiques
Amides
0
Anti-Inflammatory Agents
0
Cytokines
0
Enzyme Inhibitors
0
Ethanolamines
0
GW 6471
0
Lipopolysaccharides
0
Oxazoles
0
PPAR alpha
0
Palmitic Acids
0
beta Carotene
01YAE03M7J
Nitric Oxide
31C4KY9ESH
Tyrosine
42HK56048U
palmidrol
6R8T1UDM3V
fucoxanthinol
7176-02-5
Amidohydrolases
EC 3.5.-
NAAA protein, mouse
EC 3.5.1.-
fatty-acid amide hydrolase
EC 3.5.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Natural Science Foundation of Fujian Province
ID : No. 2018J05142
Organisme : Natural Science Foundation of Ningbo
ID : No. 2019A610209
Organisme : National Natural Science Foundation of China
ID : No. 81901133
Organisme : Scientific Research Foundation of Third Institute of Oceanography, Ministry of Natural Resources
ID : No. 2017007, No.2017026
Organisme : the Key Technology R&D Program of Fujian Province
ID : No.2018N0014
Organisme : Marine Economy Innovation Development Area Demonstration Project of Beihai
ID : Bhsfs009
Organisme : Xiamen Ocean Research and Development Institute co-construction project
ID : 2020
Références
J Med Chem. 2020 Mar 26;:
pubmed: 32191459
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:637-659
pubmed: 31580774
Mol Pharmacol. 2005 Jan;67(1):15-9
pubmed: 15465922
Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13345-50
pubmed: 16938887
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jun 15;878(20):1687-99
pubmed: 20462810
Br J Pharmacol. 2002 Jan;135(1):181-7
pubmed: 11786493
J Immunol Res. 2018 Aug 1;2018:3430684
pubmed: 30155492
J Invest Dermatol. 2018 Mar;138(3):562-569
pubmed: 29054595
J Pharm Biomed Anal. 2019 Feb 5;164:155-163
pubmed: 30390557
Mar Drugs. 2015 Jul 31;13(8):4784-98
pubmed: 26264004
Expert Opin Ther Targets. 2012 Nov;16(11):1113-25
pubmed: 22925108
Cell Death Dis. 2014 Aug 28;5:e1397
pubmed: 25165883
Eur J Med Chem. 2020 Feb 15;188:111953
pubmed: 31945644
J Biol Chem. 2000 Nov 24;275(47):36703-7
pubmed: 10980195
Anticancer Res. 2015 Jan;35(1):207-19
pubmed: 25550553
Molecules. 2018 Dec 29;24(1):
pubmed: 30597991
J Biol Chem. 2003 Nov 7;278(45):45034-9
pubmed: 12949078
Molecules. 2019 Jul 12;24(14):
pubmed: 31336903
Int J Mol Med. 2006 Jul;18(1):147-52
pubmed: 16786166
Mar Drugs. 2012 Mar;10(3):604-16
pubmed: 22611357
J Biol Chem. 2017 Feb 3;292(5):1724-1736
pubmed: 27927986
Drug Discov Today. 2014 Oct;19(10):1632-9
pubmed: 24952959
Clin Exp Pharmacol Physiol. 2020 Apr;47(4):543-552
pubmed: 31868943
Crit Rev Biochem Mol Biol. 2016;51(1):7-14
pubmed: 26585314
Int J Oncol. 2013 Oct;43(4):1176-86
pubmed: 23857515
Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10032-E10040
pubmed: 30301806
Eur J Pharmacol. 2010 Dec 15;649(1-3):369-75
pubmed: 20868674
J Agric Food Chem. 2013 Apr 24;61(16):3876-83
pubmed: 23551304
Neuropharmacology. 2019 Jan;144:327-336
pubmed: 30439418
J Immunol. 2016 Jun 1;196(11):4739-49
pubmed: 27183583
J Biol Chem. 1999 Nov 5;274(45):32048-54
pubmed: 10542237
Am J Respir Crit Care Med. 2016 Jan 15;193(2):116-30
pubmed: 26583808
Biochimie. 2010 Jun;92(6):724-7
pubmed: 20096327
J Pharmacol Exp Ther. 2008 Jul;326(1):12-23
pubmed: 18367664
Front Pharmacol. 2019 Aug 28;10:906
pubmed: 31555126
Mar Drugs. 2015 Aug 04;13(8):4799-813
pubmed: 26248075
Diabetes. 2005 Aug;54(8):2460-70
pubmed: 16046315
Neuroscience. 2010 Mar 10;166(1):252-62
pubmed: 19963043
Arch Biochem Biophys. 2010 Dec 1;504(1):17-25
pubmed: 20515643
Crit Rev Immunol. 2011;31(5):379-446
pubmed: 22142165
Mar Drugs. 2015 May 29;13(6):3422-42
pubmed: 26035021
Medicina (Kaunas). 2019 Apr 01;55(4):
pubmed: 30939862
Front Microbiol. 2018 Aug 20;9:1936
pubmed: 30177926
Pharmacol Res. 2019 Jul;145:104264
pubmed: 31063807
Mar Drugs. 2015 Apr 13;13(4):2196-214
pubmed: 25871295
Inflamm Allergy Drug Targets. 2013 Oct;12(5):349-61
pubmed: 23876224
Inflammation. 2014 Apr;37(2):443-50
pubmed: 24146106
Biochim Biophys Acta. 2007 May;1771(5):623-32
pubmed: 17462942
Eur J Pharmacol. 2009 Jun 24;613(1-3):54-9
pubmed: 19386271
J Hepatol. 2015 Mar;62(3):720-33
pubmed: 25450203
Pharmacol Res. 2018 Jun;132:7-14
pubmed: 29572189
Annu Rev Physiol. 2017 Feb 10;79:567-592
pubmed: 27959619
J Immunol. 2017 Jul 1;199(1):17-24
pubmed: 28630109
Sci Rep. 2015 Aug 27;5:13565
pubmed: 26310614
J Nat Prod. 2019 Aug 23;82(8):2307-2331
pubmed: 31403790
Food Chem. 2019 Jan 1;270:481-486
pubmed: 30174076